Skip to content

US · TLPH · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Talphera, Inc. (TLPH) intrinsic value and stock valuation

$0.79as of 2026-11-21 · Mkt cap 29.34M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Talphera, Inc. DCF and intrinsic value

InvestorsCraft values TLPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TLPH’s statements →

Talphera, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic San Mateo, CA 94404 talphera.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$30K-64.6% 5y CAGRd
20112025
Net income
-$-14.29M
20112025
Free cash flow
-$-11.36M
20112025
Total equity
$17M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$30K$0.00$650K$0.00$380K
Operating income-$-13.48M-$-15.25M-$-16.89M-$-20.35M-$-18.12M
Net income-$-14.29M-$-13M-$-18.4M$42.5M-$-35.1M
EPSd-$-336.95K-$-502.9K-$-1.29M$5.74M-$-5.86M
Operating cash flow-$-11.36M-$-12.68M-$-17.49M-$-28.33M-$-30M
Capital expenditure$0.00$0.00-$-100K-$-360K-$-1.83M
Free cash flow-$-11.36M-$-12.68M-$-17.59M-$-28.7M-$-31.83M
Total assets$29.7M$18.2M$20.4M$47.5M$77.9M
Total debt$6.5M$6.53M$0.00$10M$18.6M
Net debt$600K-$-2.34M-$-5.72M-$-5.25M$11M
Total equity$17M$8M$14.1M$21.8M-$-35.89M
Cash and short-term investments$20.4M$8.86M$9.38M$15.8M$46.6M
Income statement
20252024202320222021
Revenue$30K$0.00$650K$0.00$380K
Cost of revenue$0.00$6.72M$5.55M$1.65M$3.01M
Gross profit$30K-$-6.72M-$-4.89M-$-1.65M-$-2.63M
Research and development expenses$6.03M$6.72M$5.55M$1.69M$2.44M
Selling, general and administrative expenses$7.48M$0.00$0.00$17M$0.00
Other expenses$0.00$1.82M$6.45M$0.00$13.1M
Operating expenses$13.5M$8.53M$12M$18.7M$15.5M
Cost and expenses$13.5M$15.3M$17.5M$20.4M$18.5M
Interest income$440K$680K$6.74M$1.5M$3.16M
Interest expense$0.00$390K$130K$1.12M$2.29M
Depreciation and amortization$0.00$100K$100K$1.65M$1.97M
Ebitda-$-14.36M-$-12.51M-$-10.06M$61.9M-$-12.88M
Operating income-$-13.48M-$-15.25M-$-16.89M-$-20.35M-$-18.12M
Total other income/expenses, net-$-880K$2.25M$6.6M$79.5M$970K
Income before tax-$-14.36M-$-13M-$-10.29M$59.1M-$-17.15M
Income tax expense$0.00$0.00$0.00$10K$10K
Net income-$-14.29M-$-13M-$-18.4M$42.5M-$-35.1M
Weighted average shares outstanding$42.4M$25.9M$14.3M$7.41M$5.99M
Weighted average diluted shares outstanding$42.4M$25.9M$14.3M$7.41M$5.99M
Balance sheet
20252024202320222021
Cash and short-term investments$20.4M$8.86M$9.38M$15.8M$46.6M
Net receivables$0.00$0.00$0.00$310K$160K
Inventory$0.00$0.00$0.00$1.18M$1.11M
Total current assets$20.9M$9.42M$11.6M$24.6M$50.5M
Property, plant and equipment, net$0.00$0.00$0.00$13.9M$20.2M
Goodwill and intangible assets$0.00$8.82M$8.82M$8.82M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.82M$8.82M$8.84M$22.9M$27.4M
Total assets$29.7M$18.2M$20.4M$47.5M$77.9M
Accounts payable$540K$670K$1.34M$1.26M$2.12M
Short-term debt$0.00$0.00$0.00$7.06M$9.86M
Deferred revenue$0.00$0.00$0.00$120K$90K
Total current liabilities$3.81M$2.65M$4.51M$13.8M$18.5M
Long-term debt$6.5M$6.53M$0.00$2.96M$8.76M
Deferred revenue, non-current$0.00$0.00$0.00$1.04M$1.15M
Total non-current liabilities$8.88M$7.59M$1.78M$11.9M$95.3M
Capital lease obligations$0.00$0.00$0.00$4.66M$4.82M
Total liabilities$12.7M$10.2M$6.29M$25.7M$113.8M
Common stock$50K$20K$20K$10K$10K
Retained earnings-$-471.52M-$-457.23M-$-444.23M-$-425.83M-$-473.58M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$17M$8M$14.1M$21.8M-$-35.89M
Total investments$14.5M$0.00$3.66M$490K$39M
Total debt$6.5M$6.53M$0.00$10M$18.6M
Net debt$600K-$-2.34M-$-5.72M-$-5.25M$11M
Cash flow statement
20252024202320222021
Net income-$-14.29M-$-13M-$-18.4M$47.8M-$-35.1M
Depreciation and amortization-$-140K-$-120K$310K$1.65M$1.97M
Stock-based compensation$700K$990K$1.73M$2.89M$4.61M
Change in working capital$1.08M-$-220K-$-1.54M-$-1.39M$200K
Accounts receivable$0.00$0.00-$-190K-$-150K$470K
Inventory$0.00$0.00$60K-$-110K-$-290K
Accounts payable-$-210K-$-670K-$-570K$550K$110K
Net cash provided by operating activities-$-11.36M-$-12.68M-$-17.49M-$-28.33M-$-30M
Investments in property, plant and equipment$0.00$0.00-$-100K-$-360K-$-1.83M
Acquisitions, net$0.00$0.00$0.00$0.00-$-820K
Net cash used for investing activities-$-14.35M$3.78M-$-530K$36.5M-$-26.12M
Common stock issued$22.7M$5.91M$8.86M$7.99M$50.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.7M$12M$3.47M-$-510K$41.5M
Net change in cash-$-2.97M$3.14M-$-14.55M$7.61M-$-14.61M
Cash at end of period$5.89M$8.86M$5.72M$20.3M$12.7M
Operating cash flow-$-11.36M-$-12.68M-$-17.49M-$-28.33M-$-30M
Capital expenditure$0.00$0.00-$-100K-$-360K-$-1.83M
Free cash flow-$-11.36M-$-12.68M-$-17.59M-$-28.7M-$-31.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Talphera, Inc.

        Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.

        CEO
        Vincent J. Angotti
        Employees
        12
        Beta
        0.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Talphera, Inc. (TLPH)?

        InvestorsCraft does not currently publish an intrinsic value for TLPH. How the IC value is calculated.

        Is TLPH undervalued?

        InvestorsCraft does not publish an undervaluation signal for TLPH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.